The preparation is commonly used across conditions characterized by periods of heightened symptoms in the anorectal region, such as acute symptomatic hemorrhoidal disease and localized inflammatory conditions. A core therapeutic application is to address pronounced and distressing symptoms, which generally include acute pain, intense burning, and severe pruritus (itching). It is also applied in settings where symptoms are a result of inflammatory or irritative states, notably localized swelling (edema) and tissue irritation. This is generally considered relevant when short-term symptomatic assistance is needed, such as during acute flare-ups or for supportive relief in pre- and post-operative scenarios.

This preparation may help address symptom clusters that may become intense or disruptive, and may assist with maintaining comfort during difficult episodes. The preparation contributes to improved day-to-day comfort by easing the overall symptom load.

“The approach is relevant for easing distressing symptoms and supporting the patient during difficult episodes by contributing to comfort.”

Quick Fact: Relief for Acute Discomfort

Symptom Domain	Condition Category	Primary Benefit
Acute Pain, Burning, Pruritus	Acute Symptomatic Hemorrhoids	Provides support that helps ease the overall symptom burden
Swelling and Tissue Irritation	Localized Inflammatory Conditions	May assist with comfort during periods of heightened symptoms

Regulatory References

1. NIH MedlinePlus Medical Encyclopedia

Who Can and Cannot Use Долопрокт?

Eligibility to use Долопрокт (Fluocortolone Pivalate and Lidocaine Hydrochloride) is defined by strict regulatory criteria concerning age, pre-existing conditions, and physiological status.

---

Contraindicated Populations

The medicine is contraindicated and must not be used by individuals with known hypersensitivity to the active substances or any amide-type local anesthetics.

Use is also prohibited in the presence of specific local infections, including tuberculous or syphilitic processes in the area to be treated, or local virus diseases such as chickenpox or genital herpes.

---

Population Restrictions

Population Group	Eligibility Status	Regulatory Basis
Pediatric (<18 years)	Not recommended	Safety and efficacy are not established.
Adults (18+ years)	Eligible	Standard established use.
First Trimester Pregnancy	Not recommended	Due to glucocorticoid component risk.
Severe Hepatic/Renal Impairment	Caution Required	Risk of Lidocaine accumulation.

---

For breastfeeding mothers and those in the second or third trimester of pregnancy, use requires caution and a clinical assessment. The label mandates that any co-existing bacterial or fungal infections must be treated simultaneously with appropriate therapy.

Interactions with other medicines and products

Official regulatory documents define the interaction profile for this topical combination primarily based on the potential for systemic absorption of its two active ingredients: the glucocorticoid Fluocortolone and the local anesthetic Lidocaine Hydrochloride.

---

Documented Interaction Restrictions

Interaction Entity	Regulatory Classification
Class III Anti-arrhythmic Drugs (e.g., Amiodarone, Sotalol)	Contraindicated Combination for use outside of a hospital setting.
CYP3A Inhibitors (e.g., Cobicistat-containing products)	Avoid Combination (expected to increase systemic corticosteroid exposure).
Other Local Anaesthetics	Use with Caution (potential for additive toxic effects).

---

Official Interaction Statements

Regulatory agencies specify that co-administration with Class III Anti-arrhythmic Drugs is documented as contraindicated outside of a hospital setting due to the risk of additive cardiac effects. Co-treatment with CYP3A Inhibitors is expected to increase the systemic exposure of the Fluocortolone component, thereby elevating the risk of systemic side-effects. Furthermore, the toxic effects are additive when the preparation is co-administered with other local anaesthetics or agents structurally related to amide-type local anaesthetics. The use of Cimetidine and Beta-Blockers is noted to inhibit Lidocaine metabolism, a risk factor for toxic plasma concentrations if the medicine is used in repeated high doses over a long time period.

Долопрокт combines two distinct active pharmacological agents: a glucocorticoid, fluocortolone pivalate, and an amino amide-type local anesthetic, lidocaine hydrochloride.

Fluocortolone pivalate penetrates target cells and functions as an agonist for the cytoplasmic glucocorticoid receptor (GR). This ligand-receptor complex translocates to the nucleus, binding to Glucocorticoid Response Elements (GREs) on the DNA. This binding modifies gene transcription, specifically promoting the expression of anti-inflammatory proteins, such as Lipocortin-1 (Annexin A1), which inhibits phospholipase A2. The inhibition of PLA2 restricts the release of arachidonic acid from membrane phospholipids, consequently suppressing the synthesis of pro-inflammatory eicosanoids, including prostaglandins and leukotrienes. Concurrently, this transcriptional modification downregulates the expression of pro-inflammatory cytokines, chemokines, and adhesive molecules. This cascade ultimately modulates local vascular permeability and cellular exudation.

Lidocaine hydrochloride functions as a non-selective inhibitor of voltage-gated Na^+ channels on neuronal cell membranes. The uncharged form of lidocaine diffuses into the axoplasm, where it ionizes and binds reversibly to the channel's intracellular binding site. This binding stabilizes the channel in the inactivated state, preventing the transient influx of Na^+ ions required for depolarization and action potential propagation. The resultant block inhibits the transmission of peripheral nerve signals.

The administration of Долопрокт is structured as a localized treatment utilizing the rectal cream or suppository dosage forms. The approved route is primarily topical for perianal application and intrarectal using a specialized applicator for internal use.

---

Administration Protocol

The standard adult dosing schedule begins with application twice a day, typically in the morning and evening. This frequency may be temporarily increased to up to three times daily during the initial phase of use, based on prescribing information. This initial approach is followed by a step-down pattern where the frequency is reduced to once per day after the initial response is achieved.

---

Procedural and Time Constraints

For procedural correctness, it is required that the anal region be thoroughly cleansed before application. Administration is also advised to occur following defecation to maximize the treatment's contact with the affected area. When using the cream intrarectally, the specialized applicator must be attached and subsequently cleaned thoroughly after each instance of use. The total duration of the treatment course is strictly time-bound, stipulating that administration must not exceed 14 days. Additionally, a population restriction is defined where the preparation is not recommended for individuals under 18 years of age.

Research Evidence / Overview of Studies for Долопрокт

---

Evidence for Acute Symptomatic Hemorrhoidal Disease

Research exploring the use of Долопрокт for acute symptomatic hemorrhoidal disease has included both short-term controlled trials and observational cohort studies. These studies were used in research exploring how symptoms change over time in adults with acute or heightened symptoms. The primary focus of measurement included patient-reported intensity of specific symptoms, such as pain, pruritus (itching), and burning, alongside physician observations of physical signs like swelling.

The findings describe patterns observed in the studies where the intensity of acute symptoms was measured and tracked over the short treatment period. Research highlights measurements taken during the study period for outcomes capturing phases of heightened symptom activity. The evidence contributes to understanding short-term symptom patterns in conditions characterized by fluctuating or episodic manifestations.

However, follow-up durations were limited, typically concentrated on the 7 to 14 days of active treatment. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes beyond the acute treatment phase.

---

Evidence for Use Before and After Anorectal Procedures

Долопрокт was evaluated in studies conducted during periods of increased symptom activity, specifically in patients undergoing anorectal surgery like hemorrhoidectomy. These trials assessed short-term symptom patterns and outcomes related to physical discomfort, such as postoperative pain intensity and the need for supplementary pain relief medication during the recovery phase.

Studies report how symptoms evolved in the observed populations during the immediate post-operative period. Research describes changes measured for pain intensity, with data showing patterns related to the use of supplementary analgesic medicines compared to control groups. The available research primarily focuses on the immediate recovery phase, typically covering the first seven days following surgery.

---

Evidence in Specific Patient Populations

The main body of clinical research was conducted in adults who met predefined criteria for symptomatic hemorrhoidal disease or post-operative care. Data for certain groups, such as children, older adults, or those with complex comorbid health conditions, remain insufficient in the primary clinical trial evidence. Specific clinical trial data for populations such as pregnant or breastfeeding individuals are not widely available in the general research summaries.

---

What Is Still Uncertain About the Research Base

While research provides insight into short-term changes, several areas remain uncharacterized or limited. Comparative evidence is lacking in some areas, such as detailed comparisons against every alternative treatment. The certainty remains low for long-term effects, as the research generally emphasizes acute, short-term relief. The evidence contributes to understanding symptom patterns, but research does not determine whether an individual will respond similarly, as individual experiences and symptom burdens vary.

Key Studies & References The effectiveness of combined topical product with fluocortolone pivalate and lidocaine for hemorrhoids: results of a multicenter observational study

Common questions about Долопрокт (FAQ)

Q: Are there side effects of Doloproct that are often discussed online?

Official regulatory documents classify the most frequent local effects as Common (affecting up to 1 in 10 people), including transient burning, irritation, and itching (pruritus). Less frequent effects (Uncommon) include local allergic skin reactions. This information establishes the officially verified frequency and nature of the discomforts users may experience.

Q: Can Doloproct be stored in the bathroom?

Official instructions state that Doloproct suppositories must generally be stored below 25°C and protected from light. Although the rectal cream often does not have special temperature requirements, the official storage conditions should be maintained. High heat and humidity, which are typical of bathrooms, are factors that can compromise product integrity.

Q: How quickly does Doloproct relieve itching?

The preparation is designed to achieve rapid symptomatic relief due to the inclusion of Lidocaine Hydrochloride, an anesthetic component known for its quick action. Official documentation describes this effect as rapid but does not typically define a specific timeframe (e.g., minutes or hours) for the onset of action.

Q: Can Doloproct interact with vitamins or supplements?

Official regulatory documents focus primarily on documented drug-drug interactions, such as those involving CYP3A inhibitors or other local anesthetics. There are no specific official statements in the product labeling regarding interactions with general vitamins or common dietary supplements.

Q: Is it mandatory to use the applicator for Doloproct ointment?

Official guidelines specify that the special applicator must be used for intrarectal (internal) application of the cream. The product is also approved for topical (external/perianal) application, which does not require the use of the applicator.

Q: Are there special instructions for elderly people when using Doloproct?

Official summaries indicate that the main clinical research was conducted in adults, and the evidence base for certain groups, including older adults, remains insufficient. Therefore, official information suggests that a cautious approach and clinical assessment are typically necessary when considering use in elderly populations.

Q: What is the difference between Doloproct ointment and suppositories?

Doloproct is supplied as a rectal cream and suppositories. The cream is designed for both external (topical) application and internal use (with an applicator), while the suppositories are solely intended for intrarectal (internal) application.

Q: What is 'withdrawal syndrome' when stopping Doloproct?

Official documents describe the potential risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression with extensive or long-term use of the corticosteroid component. The risk of HPA suppression is noted. If HPA suppression occurs, the official labeling may describe the need for a gradual discontinuation process, though a specific 'withdrawal syndrome' is not detailed in the product information.

Q: Can Doloproct be used for anal fissures?

The primary focus of clinical studies for Doloproct has been the treatment of acute symptomatic hemorrhoidal disease and use during anorectal procedures. A specific regulatory indication for the treatment of anal fissures is not explicitly listed in the summaries of research evidence.

Q: Can Doloproct be applied to damaged skin or open wounds?

Use is officially contraindicated if infectious processes (such as viral or bacterial infections) are present in the area to be treated. Applying the product to damaged skin or open wounds may also increase the risk of systemic absorption and the potential for Lidocaine-related systemic toxicity.

Q: Is it true that Doloproct can cause addiction?

Official regulatory documents do not typically discuss addiction or dependence related to this topical corticosteroid/anesthetic combination. Concerns associated with long-term use are related to local tissue changes, such as skin thinning (atrophy), and the potential for HPA axis suppression from the steroid.

Q: Are there official warnings about driving a car?

Official safety guidelines advise that undesirable effects, such as dizziness or CNS changes that may result from the systemic absorption of Lidocaine, should be considered. These effects could potentially impact the ability to drive or safely operate machinery.

Q: What symptoms indicate an overdose of Doloproct?

The primary risk associated with overdose or excessive use is the potential for Lidocaine systemic toxicity. Symptoms of systemic toxicity can include signs related to the central nervous system, such as dizziness, confusion, or seizures, as well as possible cardiovascular effects.

Storage and Disposal of Doloproct

Storage Requirements

All forms of Doloproct must be kept out of the sight and reach of children. The rectal cream often has no special temperature conditions required, while the suppositories must generally be stored below 25°C and protected from light in the original carton.

Stability and Handling

A critical constraint for the rectal cream is the in-use stability limit: the opened tube must be discarded 30 days after it is first opened, regardless of the package expiry date.

Disposal Instructions

Medicines must not be disposed of via wastewater or household waste to prevent environmental contamination. Unused or expired Doloproct must be discarded according to local regulations, such as utilizing an official drug take-back program or following local pharmacy guidance.